The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010�20

Darbandi, A. and Asadi, A. and Ghanavati, R. and Afifirad, R. and Darb Emamie, A. and kakanj, M. and Talebi, M. (2021) The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010�20. International Journal of Infectious Diseases, 105. pp. 91-104.

[img] Text
The effect of probiotics on respiratory tract infection with special emphasis on COVID-19 Systemic review 2010–20.pdf

Download (1MB)
Official URL:


To evaluate the effects of probiotics on respiratory tract infection (RTI) a systematic review of randomized controlled trials (RCTs) from January 2010 to January 2020 was conducted. The PubMed, Google Scholar, Embase, Scopus,, and International Clinical Trials Registry Platform databases were systematically searched for the following keywords: respiratory tract infection, probiotics, viral infection, COVID-19, and clinical trial. A total of 27 clinical trials conducted on 9433 patients with RTI plus 10 ongoing clinical studies of probiotics intervention in Coronavirus disease 2019 (COVID-19) were reviewed. The review looked at the potency of probiotics for the hindrance and/or treatment of RTI diseases, this may also apply to COVID-19. The review found that probiotics could significantly increase the plasma levels of cytokines, the effect of influenza vaccine and quality of life, as well as reducing the titer of viruses and the incidence and duration of respiratory infections. These antiviral and immune-modulating activities and their ability to stimulate interferon production recommend the use of probiotics as an adjunctive therapy to prevent COVID-19. Based on this extensive review of RCTs we suggest that probiotics are a rational complementary treatment for RTI diseases and a viable option to support faster recovery. © 2021 The Authors

Item Type: Article
Additional Information: cited By 1
Uncontrolled Keywords: immunoglobulin A; immunoglobulin G; immunoglobulin M; influenza vaccine; Influenza virus hemagglutinin; interferon; prebiotic agent; probiotic agent; tumor necrosis factor; virus antibody; probiotic agent, abdominal pain; adult; aged; antibody titer; antiviral activity; bactericidal activity; child; chill; coronavirus disease 2019; coughing; diarrhea; disease duration; drug efficacy; female; fever; flatulence; gastrointestinal symptom; headache; human; immunoglobulin blood level; immunomodulation; influenza A (H1N1); influenza A (H3N2); interferon production; male; memory cell; middle aged; myalgia; natural killer cell; nausea; neutrophil; phagocytosis; preschool child; protein blood level; quality of life; randomized controlled trial (topic); respiratory tract infection; Review; rhinorrhea; seroconversion; sore throat; systematic review; vaccination; very elderly; virus load; vomiting; weakness; young adult; immunology; prevention and control; respiratory tract infection, COVID-19; Humans; Probiotics; Respiratory Tract Infections; SARS-CoV-2
Subjects: WC Communicable Diseases
WF Respiratory System
Depositing User: eprints admin
Date Deposited: 29 Oct 2022 10:36
Last Modified: 29 Oct 2022 10:36

Actions (login required)

View Item View Item